Bronchial Asthma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with asthma (including ACO) according to the Asthma Prevention and Management Guideline 2015 2) Patients who can provide written informed consent to participate in the study 3) Outpatients at least 20 and under 80 years of age 4) Patients continuing ICS/LABA treatment for at least 4 weeks 5) Patients who have been visiting the clinic/hospital for at least the previous 1 year 6) Patients with no communication problems
Exclusion criteria
Exclusion criteria: 1) Patients with a concomitant malignant tumor 2) Patients with apparent COPD 3) Patients with a history of respiratory infection (including viral infection) within the past 4 weeks 4) Patients who are breastfeeding, pregnant, or hoping to become pregnant during the study period 5) Other patients who are judged unsuitable for participation by the Principal or Sub Investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the GAP between JGL-JACS and JGL-ACQ at Week 0 Comparison of the agreement of asthma control levels based on JACS against JGL and ACQ against JGL | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Evaluation at Week 0 and Week 24 - Agreement of control levels between each control evaluation (JGL, GINA, ACQ, JACS) - Agreement of treatment satisfaction (patient-physician evaluated) - Correlation between control levels and treatment satisfaction (2) The changes from Week 0 to Week 24 - Frequency of exacerbation (unscheduled clinic/hospital visits, use of systemic steroids) - Period until exacerbation - Change in each control evaluation - Change in treatment satisfaction (physician and patient) - Change in respiratory function - Change in the GAP of control levels (physician-patient) - Change in the GAP between control levels and treatment satisfaction (between patients, between physicians) (3) Cluster analysis at Week 0 - Long-term control medication - Each patient background characteristic - Result of control levels and treatment satisfaction - Respiratory function - Type of medical facility - Presence or absence of ACO (4) Cluster analysis for exacerbation | — |
Countries
Japan
Contacts
Mebix, Inc. Research Promotion Group